🇺🇸 FDA
Patent

US 11084850

Recombinant prefusion RSV F proteins and uses thereof

granted A61KA61K2039/5258A61K2039/545

Quick answer

US patent 11084850 (Recombinant prefusion RSV F proteins and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/5258, A61K2039/545, A61K2039/552, A61K2039/55505